AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04984447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNIB Catheter
Description: Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
Study NCT02231073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Education for Parkinson's Disease
Description: Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
Study NCT02231073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Education for Parkinson's Disease
Description: Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
Study NCT04668430 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: imaging and motion analysis
Description: performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
Study NCT02472990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No drug and no placebo were used in this study
Description: measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
Study NCT00768170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: MK0633 (50 mg) Oral, single dose
Study NCT05635942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized quadruple therapy
Description: Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Study NCT05635942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard quadruple therapy
Description: Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Study NCT03952052 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of mutation
Description: Recurrent mutation determination by digital PCR and next generation sequencing
Study NCT03474926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Template-based lymphadenectomy
Description: Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue.
Study NCT03474926 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LND only for lymph nodes enlargement found in preoperative image or during surgery
Description: LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
Study NCT02395029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)
Study NCT03992131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered per schedule specified in the arm description.
Study NCT03992131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib will be administered per schedule specified in the arm description.
Study NCT03992131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan will be administered per schedule specified in the arm description.
Study NCT04210167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based training and telephone monitoring
Description: web-based training and telephone monitoring and short message
Study NCT04224857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-101
Description: Single or daily dosing at doses A, B, C, D, E, F
Study NCT04224857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Single or daily dosing at doses A, B, C, D, E, F
Study NCT04641676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS testing
Description: NGS test will be performed
Study NCT04641676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NGS testing
Description: NGS test will be performed
Study NCT00261976 — intervention group
Intervention type: DRUG
Intervention: Infliximab (Remicade)
Description: This is an non-interventional study. Participants took the study product as part of their medical routine.
Study NCT03697317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Televideo Lifestyle Coaching
Description: Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
Study NCT03697317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
Study NCT00700700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Cardiac Resynchronization Therapy (CRT)
Description: Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750
Study NCT05330676 — intervention group
Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting, valve repair/replacement
Description: cardiovascular surgery with cardiopulmonary bypass
Study NCT00920322 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS 5 x weekly
Description: Patients will receive rTMS five times weekly for 4 weeks
Study NCT06132971 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Study NCT00920322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS 3 times weekly
Description: Patients will receive rTMS 3 times weekly for 4 weeks
Study NCT02984722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03340831 — intervention group
Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
Study NCT01361594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (intensive treatment)
Description: Titration of the IV insulin rate for glucose goal 100-140 mg/dL
Study NCT01361594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin (conventional treatment)
Description: Titration of the IV insulin rate for glucose goal 141-180 mg/dl
Study NCT02716259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
Study NCT02716259 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supragingival prophylaxis
Description: Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
Study NCT02753153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control surgical protocol
Description: A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0).
Study NCT02753153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test surgical protocol
Description: The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
Study NCT02753153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied.
Study NCT06132971 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: New Beginnings Program
Study NCT03843996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment - Stratamed
Description: To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
Study NCT04020536 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Study NCT02966704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intrinsically labeled milk protein
Study NCT04249479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CM Temperature (20° C)
Description: CM will be administered at 20° C (room temperature).
Study NCT04249479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM Temperature (37° C)
Description: CM will be administered at 37° C (pre-heated).
Study NCT04249479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight
Description: The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
Study NCT04249479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight
Description: The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
Study NCT02147171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VisionAce
Study NCT02147171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00723229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: Acyclovir 400 mg PO BID for 28 days
Study NCT01062191 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel AG, typical carboxymethylcellulose dressing
Description: 4 X 4, Aquacel silver sheet
Study NCT01062191 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Description: Wound dressing
Study NCT02753153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation
Description: An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied.
Study NCT00680446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G (Ig NextGen 16%)
Description: Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
Study NCT02392052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinvention Protocol Participants
Description: A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
Study NCT02392052 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
Study NCT01143181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
Study NCT00359983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenHibrix (Hib-MenCY-TT)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
Study NCT00359983 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (ActHIB)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
Study NCT00359983 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib conjugate vaccine (ActHIB)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
Study NCT02320981 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
Study NCT02830126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower Feedback
Description: Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
Study NCT01763515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Description: Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
Study NCT04573348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Savicell's ImmunoBiopsy™
Description: ImmunoBiopsy and ELISA
Study NCT03262662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: oral varenicline tablets
Study NCT03262662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: oral varenicline tablets
Study NCT03262662 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation counseling
Description: \~10-minute individual counseling at each of 6 clinic visits
Study NCT03262662 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief smoking cessation counseling
Description: \~10-minute individual counseling at each of 6 clinic visits
Study NCT01680640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The synbiotic to be used is fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
Study NCT01680640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study NCT01209234 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Education
Description: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
Study NCT01209234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRSA Decolonization
Description: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
Study NCT01353651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment using self expandable nitinol STENTS
Description: A direct stenting will be performed.
Study NCT01353651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair treatment
Description: The surgeon will perform its usual technique to revascularize the common femoral artery
Study NCT02324400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenaSense Stimulation
Description: RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
Study NCT02324400 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RenaSense Sham Control
Description: RenaSense Catheter,no delivery of stimulation
Study NCT01140295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol, senna
Description: Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days.
Study NCT01966172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: oral ibuprofen 400mg 4 times daily
Study NCT01966172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Oral Gabapentin 300mg twice daily
Study NCT01966172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 10 mg morphine orally 4 times daily
Study NCT01966172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: oral paracetamol 1000mg four times daily
Study NCT01966172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: oral paracetamol 1000mg four times daily
Study NCT02971761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm
Description: Given PO
Study NCT02971761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02971761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02756221 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
Study NCT02756221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
Study NCT06424431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stapler combined with electrocautery
Description: Closure with a closure device combined with electrocoagulation for pancreatic stump closure in distal pancreatectomy
Study NCT06424431 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: simple closure with a closure device
Description: Simple closure with a closure device for pancreatic stump closure in distal pancreatectomy
Study NCT02390700 — intervention group
Intervention type: BIOLOGICAL
Intervention: Golimumab Intravenous
Description: This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
Study NCT01600248 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online ABBT for Chronic Pain in Military
Description: Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
Study NCT01827995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self assessment
Description: Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
Study NCT01827995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine assessment
Description: Follow up in the clinic